Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) EBITDA (2019 - 2025)

Revolution Medicines has reported EBITDA over the past 7 years, most recently at -$364.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$364.8 million for Q4 2025, down 85.11% from a year ago — trailing twelve months through Dec 2025 was -$1.2 billion (down 81.91% YoY), and the annual figure for FY2025 was -$1.1 billion, down 88.45%.
  • EBITDA for Q4 2025 was -$364.8 million at Revolution Medicines, down from -$303.4 million in the prior quarter.
  • Over the last five years, EBITDA for RVMD hit a ceiling of -$37.4 million in Q1 2021 and a floor of -$364.8 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$108.4 million (2023), compared with a mean of -$135.9 million.
  • Biggest five-year swings in EBITDA: decreased 16.62% in 2022 and later plummeted 159.49% in 2023.
  • Revolution Medicines' EBITDA stood at -$52.9 million in 2021, then decreased by 16.62% to -$61.7 million in 2022, then plummeted by 159.49% to -$160.1 million in 2023, then fell by 23.07% to -$197.1 million in 2024, then plummeted by 85.11% to -$364.8 million in 2025.
  • The last three reported values for EBITDA were -$364.8 million (Q4 2025), -$303.4 million (Q3 2025), and -$264.7 million (Q2 2025) per Business Quant data.